Drugs / TNKase
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TNKASE | — | 2025-02-28 | fda.gov ↗ |
| Approved | US (FDA) | TNKASE | — | 2000-06-02 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04558125 | Sep 2020 → Jul 2021 | COVID-19, pulmonary embolism | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-03 | Genentech, Inc. | FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults gene.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNKase | “1. TNKase (0.25 mg/kg) bolus Other names: Tenecteplase, TNK” NCT04558125 ↗ |
| Route | Intravenous | “low-dose IV bolus tenecteplase (TNK)” NCT04558125 ↗ |